Brokers Offer Predictions for CRGX FY2025 Earnings

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Equities researchers at Chardan Capital issued their FY2025 EPS estimates for shares of CARGO Therapeutics in a research note issued on Monday, March 24th. Chardan Capital analyst G. Livshits forecasts that the company will post earnings per share of ($3.59) for the year. Chardan Capital has a “Neutral” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for CARGO Therapeutics’ FY2026 earnings at ($3.58) EPS.

A number of other brokerages also recently weighed in on CRGX. Jefferies Financial Group downgraded shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the company from $32.00 to $3.00 in a report on Thursday, January 30th. William Blair cut shares of CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 30th. JPMorgan Chase & Co. cut CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a report on Thursday, January 30th. HC Wainwright lowered CARGO Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, January 30th. Finally, Truist Financial lowered CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the company from $32.00 to $7.00 in a research note on Thursday, January 30th. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $15.00.

CARGO Therapeutics Stock Performance

NASDAQ CRGX opened at $4.17 on Thursday. CARGO Therapeutics has a twelve month low of $3.00 and a twelve month high of $25.45. The stock has a market capitalization of $192.04 million, a PE ratio of -0.98 and a beta of 1.65. The stock has a 50-day simple moving average of $5.51 and a 200 day simple moving average of $13.71.

Hedge Funds Weigh In On CARGO Therapeutics

Several large investors have recently made changes to their positions in the company. Red Tree Management LLC bought a new stake in CARGO Therapeutics during the 4th quarter worth about $30,293,000. TRV GP VI LLC bought a new stake in shares of CARGO Therapeutics during the fourth quarter worth approximately $26,924,000. TRV GP V LLC bought a new stake in shares of CARGO Therapeutics during the fourth quarter worth approximately $25,051,000. Geode Capital Management LLC lifted its holdings in CARGO Therapeutics by 80.6% in the third quarter. Geode Capital Management LLC now owns 838,279 shares of the company’s stock valued at $15,469,000 after buying an additional 374,018 shares during the period. Finally, Sio Capital Management LLC bought a new position in CARGO Therapeutics in the third quarter valued at approximately $3,208,000. Institutional investors and hedge funds own 93.16% of the company’s stock.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.